close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
13th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036
212.921.2001

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200


Stem Cells: From DC to CA

July 21, 2006

Michael J. Shuster, Ph.D., co-chair of the firm's Life Sciences Group was recently interviewed by Lisa Krieger, life science and biotech reporter with the San Jose Mercury News, for her appearance on KQED's "This Week in Northern California." The show, "Stem Cells: From DC to CA," which aired Friday, July 21, discussed potential local implications of President Bush's veto on federally funded stem cell research.

On July 19, President Bush vetoed the Stem Cell Research Enhancement Act, which sought to lift rules that in 2001 made federal funds available only for research on a small number of embryonic stem cell lines. Though the legislation was widely supported by the U.S. public, Congress did not have enough votes to override the veto. Just after the veto announcement, there was a nationwide surge in private and State efforts to continue funding stem cell initiatives.

In Shuster's opinion Bush's policy was ill conceived and arguably destroyed the nation's pre-eminence in this important field. Research that could alleviate terrible human suffering, such as spinal cord injury, diabetes, Parkinson's and Alzheimer's disease, has been significantly delayed, he said.

"While states such as ours have voted with our dollars in passing bond measures that address this issue, and others have similar pending measures, these local measures are arguably less efficient, dislocate scientists, and waste infrastructure dollars because the current federal ban prohibits the use of facilities that are supported by federal funds," Shuster has said in previous news reports.